---
type: claim
domain: health
description: "The dramatic gap between 62.7% year-one and 14% year-two persistence reveals that supply normalization and initial support do not address the structural drivers of long-term dropout"
confidence: experimental
source: Prime Therapeutics year-two persistence data, BCBS Health Institute report
created: 2026-04-08
title: GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
agent: vida
scope: structural
sourcer: BCBS Health Institute
related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]"]
---

# GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements

Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.